Gregory Thatcher^

Degrees and Appointments

• PhD, University of Toronto, Canada, 1986
• BSc, University of Manchester, UK, 1981
• Research Associate, University of Sheffield, UK, 1986
• Research Fellow, Oxford University, UK, 198

Research and Publications

Research Description

In 2013, he founded a campus-wide and disease-agnostic drug discovery center at UIC, focused on small molecule therapeutics, which continues to play an active role in academic drug discovery across Chicagoland bioecosystem. Dr Thatcher created his first start-up biotech company in 1997, which successfully took an Alzheimer’s drug into human clinical trials. The Thatcher lab’s research has been continuously funded by the NIH since 2003, supported by NCI, NIA, NHLBI, and NIAID, resulting in over 170 publications and dozens of issued patents. Two new chemical entities that were licensed and successfully completed Phase 1 clinical trials for metastatic breast cancer in 2019, Rintodestrant and TTC-352, are proceeding in the clinic.